Organon & Co.
OGN
Get informed when a big investor buys or sells
+ Follow
Current Fair Value
20.6% upsideUndervalued by 20.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.56 Billion |
|---|---|
| Enterprise Value | $3.57 Billion |
| Dividend Yield | $0.08 (0.59%) |
| Earnings per Share | $0.72 |
| Beta | 1.54 |
| Outstanding Shares | 262,611,000 |
Return
| Return on Equity | 10050.50% |
|---|---|
| Return on Assets | 767.25% |
| Return on Invested Capital | 8259.07% |
Valuation & Multiples
| P/E Ratio | 16.94 |
|---|---|
| PEG | -66.38 |
| Price to Sales | 0.8 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.78 |
| Enterprise Value to EBIT | 4.09 |
| Enterprise Value to Net Income | 35 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 8.59 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 133.23% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | 8,900▼ 99.74% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.06%▼ 75.73% |
|---|---|
| Total Invested | $37.50M▼ 96.86% |
| Investors Holding | 149▼ 469.00% |
ESG Score
No data
About Organon & Co.
Relevant Senate Committees
This powerful committee controls taxation, trade, and entitlement spending. Its decisions on corporate tax policy, Medicare drug pricing, and international trade agreements directly and significantly impact Organon's profitability and market access.
This committee directly allocates discretionary federal spending. Its subcommittees determine funding for regulatory bodies (FDA), research (NIH), and major healthcare programs (Medicare/Medicaid), critically impacting Organon's regulatory environment and market demand.
This is a primary regulatory committee for Organon, with direct oversight of the FDA (drug approval) and NIH (research funding), as well as labor laws that impact manufacturing operations.
This committee oversees intellectual property (patents) and antitrust laws, both critical to the pharmaceutical industry. IP protection is fundamental to drug development, and antitrust actions impact M&A strategies for companies like Organon.
The committee oversees the Department of Veterans Affairs, which is a major purchaser and healthcare provider. Its funding decisions directly impact government healthcare contractors and demand for pharmaceutical products like those manufactured by Organon.